Published in J Infect Dis on July 10, 2003
A genome-wide survey of structural variation between human and chimpanzee. Genome Res (2005) 2.61
Chronic HIV-1 infection frequently fails to protect against superinfection. PLoS Pathog (2007) 2.38
Retroviral superinfection resistance. Retrovirology (2005) 1.82
Evidence for frequent reinfection with human immunodeficiency virus type 1 of a different subtype. J Virol (2005) 1.77
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J Virol (2008) 1.73
Identification of HIV superinfection in seroconcordant couples in Rakai, Uganda, by use of next-generation deep sequencing. J Clin Microbiol (2011) 1.61
The rates of HIV superinfection and primary HIV incidence in a general population in Rakai, Uganda. J Infect Dis (2012) 1.49
Partial protection of Simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J Virol (2009) 1.28
Identifying HIV-1 dual infections. Retrovirology (2007) 1.25
HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog (2013) 1.21
Frequency and implications of HIV superinfection. Lancet Infect Dis (2013) 1.19
HIV-1 superinfection in the antiretroviral therapy era: are seroconcordant sexual partners at risk? PLoS One (2009) 1.16
ABC for people with HIV: responses to sexual behaviour recommendations among people receiving antiretroviral therapy in Jinja, Uganda. Cult Health Sex (2011) 1.15
Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol (2004) 1.15
Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women. Retrovirology (2009) 1.03
Timing and source of subtype-C HIV-1 superinfection in the newly infected partner of Zambian couples with disparate viruses. Retrovirology (2012) 0.95
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. J Clin Microbiol (2013) 0.87
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses (2010) 0.86
Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine. Int Rev Immunol (2009) 0.83
Polyvalent AIDS vaccines. Curr HIV Res (2010) 0.82
Complementation in cells cotransfected with a mixture of wild-type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes of mutant variants in a single-cycle HIV resistance assay. J Clin Microbiol (2004) 0.80
A gp41-based heteroduplex mobility assay provides rapid and accurate assessment of intrasubtype epidemiological linkage in HIV type 1 heterosexual transmission Pairs. AIDS Res Hum Retroviruses (2012) 0.80
A Multi-Vector, Multi-Envelope HIV-1 Vaccine. J Pediatr Pharmacol Ther (2007) 0.78
Clade, Country and Region-specific HIV-1 Vaccines: Are they necessary? AIDS Res Ther (2005) 0.78
Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. BMC Infect Dis (2013) 0.78
SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development? Curr HIV Res (2009) 0.78
HIV competition dynamics over sexual networks: first comer advantage conserves founder effects. PLoS Comput Biol (2015) 0.76
HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogen. Hum Vaccin (2009) 0.76
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Gender differences in HIV-1 diversity at time of infection. Nat Med (2000) 4.69
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
A patient with HIV-1 superinfection. N Engl J Med (2002) 2.93
Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses (1992) 2.72
Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68
Accurate reconstruction of a known HIV-1 transmission history by phylogenetic tree analysis. Proc Natl Acad Sci U S A (1996) 2.57
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol (2001) 2.45
Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. Proc Natl Acad Sci U S A (1998) 2.23
Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. The Transfusion Safety Study Group. J Virol (1995) 2.15
Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis (2001) 1.97
Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor. J Virol (1995) 1.85
Very young gay and bisexual men are at risk for HIV infection: the San Francisco Bay Area Young Men's Survey II. J Acquir Immune Defic Syndr (2000) 1.84
Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol (2002) 1.80
Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS (1999) 1.65
Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis (2002) 1.38
Synonymous-non-synonymous mutation rates between sequences containing ambiguous nucleotides (Syn-SCAN). Bioinformatics (2002) 1.27
Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis (2002) 1.20
Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob Agents Chemother (2002) 1.20
Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. J Gen Virol (2000) 1.06
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15
Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res (2003) 10.50
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
Distributed neural representation of expected value. J Neurosci (2005) 6.85
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res (2007) 5.95
Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis (2006) 5.90
Viral population estimation using pyrosequencing. PLoS Comput Biol (2008) 5.89
New DNA viruses identified in patients with acute viral infection syndrome. J Virol (2005) 5.26
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 4.57
Metagenomic analyses of viruses in stool samples from children with acute flaccid paralysis. J Virol (2009) 4.14
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94
Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci U S A (2006) 3.76
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis (2009) 3.39
A newly identified bocavirus species in human stool. J Infect Dis (2009) 3.25
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
A highly prevalent and genetically diversified Picornaviridae genus in South Asian children. Proc Natl Acad Sci U S A (2008) 3.12
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis (2009) 3.08
Bat guano virome: predominance of dietary viruses from insects and plants plus novel mammalian viruses. J Virol (2010) 3.03
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol (2003) 2.98
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis (2005) 2.86
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
Multiple diverse circoviruses infect farm animals and are commonly found in human and chimpanzee feces. J Virol (2009) 2.70
Human bocaviruses are highly diverse, dispersed, recombination prone, and prevalent in enteric infections. J Infect Dis (2010) 2.66
A novel rhabdovirus associated with acute hemorrhagic fever in central Africa. PLoS Pathog (2012) 2.63
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr (2006) 2.56
Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis (2011) 2.54
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr (2010) 2.47
The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol (2006) 2.44
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution. Proc Natl Acad Sci U S A (2008) 2.28
HIV sequence databases. AIDS Rev (2003) 2.20
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology (2008) 2.14
Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS One (2007) 2.09
The fecal viral flora of California sea lions. J Virol (2011) 2.06
The fecal virome of pigs on a high-density farm. J Virol (2011) 2.03
High variety of known and new RNA and DNA viruses of diverse origins in untreated sewage. J Virol (2012) 2.03
Novel parvovirus and related variant in human plasma. Emerg Infect Dis (2006) 2.03
Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion (2007) 2.02
Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol (2008) 1.96
Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother (2004) 1.82
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr (2005) 1.80
HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis (2011) 1.80
The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics (2009) 1.80
Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology (2008) 1.79
HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol (2007) 1.78
High frequencies of exposure to the novel human parvovirus PARV4 in hemophiliacs and injection drug users, as detected by a serological assay for PARV4 antibodies. J Infect Dis (2009) 1.78
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS (2003) 1.78
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2009) 1.73
Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72
Deformation-based surface morphometry applied to gray matter deformation. Neuroimage (2003) 1.71
HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs (2012) 1.70
Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J Acquir Immune Defic Syndr (2005) 1.68
Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis (2007) 1.66
Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS (2004) 1.65
Acute diarrhea in West African children: diverse enteric viruses and a novel parvovirus genus. J Virol (2012) 1.64
Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther (2008) 1.58
Biomarker discovery using targeted maximum-likelihood estimation: application to the treatment of antiretroviral-resistant HIV infection. Stat Med (2009) 1.57
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS (2010) 1.54
HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother (2010) 1.53
Divergent astrovirus associated with neurologic disease in cattle. Emerg Infect Dis (2013) 1.51
Viruses in diarrhoeic dogs include novel kobuviruses and sapoviruses. J Gen Virol (2011) 1.50
Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol (2012) 1.48
Discovery of a novel polyomavirus in acute diarrheal samples from children. PLoS One (2012) 1.48
A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. AIDS (2014) 1.47
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis (2005) 1.47
Serological studies confirm the novel astrovirus HMOAstV-C as a highly prevalent human infectious agent. PLoS One (2011) 1.46
Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor. Clin Infect Dis (2009) 1.46
Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. PLoS One (2010) 1.46
Identification and characterization of a new bocavirus species in gorillas. PLoS One (2010) 1.46
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis (2012) 1.46
Widespread infection with homologues of human parvoviruses B19, PARV4, and human bocavirus of chimpanzees and gorillas in the wild. J Virol (2010) 1.42
HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS (2006) 1.40
Characterization of the gene expression profile of human bocavirus. Virology (2010) 1.40
Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS (2005) 1.39
HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. J Acquir Immune Defic Syndr (2003) 1.38
Seroepidemiology of human bocaviruses 1-4. J Infect Dis (2011) 1.37